No abstract available.
Calcium* ; Cyclic GMP* ; Muscle Cells*

BACKGROUND/AIMS: Lamivudine, an oral nucleoside analogue, effectively inhibits hepatitis B virus replication and reduces hepatic necroinflammation in patients with chronic hepatitis B. This study investigated the effect and safety of 12 week lamivudine therapy in Korean patients with chronic hepatitis B (CHB). METHODS: In an open clinical trial, 113 patients with CHB were enrolled. They received 100 mg of lamivudine orally once daily for 12 weeks, and they were followed until 2 weeks after cessation of lamivudine. HBV DNA (by bDNA assay), liver enzymes, creatine phosphokinase, creatinine and CBC were checked at 0, 2, 4, 8, 12 and 14 weeks. Compliance and side effects were evaluated at the same time. RESULTS: After receiving lamivudine 100 mg, serum HBV DNA levels fell rapidly, remaining in 94.3% below baseline values at 2 weeks and 99.8% below baseline values at 12 weeks. Serum HBV DNA was cleared in 75.2% and alanine aminotransferase level (ALT) was normalized in 64.8% at 12 weeks. Cumulative percentage of HBeAg clearance (defined by clearance of serum HBV DNA and HBeAg) was 14.4%. Clearance of HBV DNA was more frequent in patients with lower pretreatment serum HBV DNA and higher ALT. During the treatment periods, adverse effects were negligible and transient. Two weeks after cessation of lamivudine, serum HBV DNA reappeared in 70.6% of responders. CONCLUSION: It is suggested that lamivudine is effective and safe in the treatment of CHB in Korean patients, but further study for adequate duration of treatment is needed because of high recurrence after 12 weeks therapy.
Alanine Transaminase ; Compliance ; Creatine Kinase ; Creatinine ; DNA ; Hepatitis B e Antigens ; Hepatitis B virus ; Hepatitis B, Chronic* ; Hepatitis, Chronic* ; Humans ; Lamivudine* ; Liver ; Recurrence

BACKGROUND: During laryngoscopy, force applied to the soft tissue are assumed to cause circulatory response. The aim of the study was to evaluate this circulatory response and to analyze the relationship between the intensity of the force and the magnitude of the associated circulatory responses. METHODS: Sixty-three healthy patients, aged 17 to 29 years, were randomly allocated to one of three groups according to the three different subjective forces applied intentionally. Subjects in group 1 received minimal force enough to stimulate circulatory response, but not enough to expose the glottis. Group 2 received the optimal force necessary to expose the glottic opening. Group 3 received excessive force to expose the glottic opening. The axial forces of the laryngoscope handle with a Macintosh blade were measured during a ten-second laryngoscopy, and peak force, mean force, and area under the curve were calculated. Then, arterial pressure and heart rate were recorded after the laryngoscopy at 30 seconds intervals for 3 minutes. The data was compared among groups and with the baseline post-induction values. RESULTS: No significant difference was found in heart rate and blood pressure at each interval among the three groups, with increasing arterial pressure and heart rate after the laryngoscopy. Blood pressure and heart rate were maintained high, being progressively higher in the groups receiving a higher force. CONCLUSIONS: We conclude that little association was found between the force and the magnitude of circulatory response although higher forces cause longer circulatory responses.
Arterial Pressure ; Blood Pressure ; Glottis ; Heart Rate ; Humans ; Intention ; Laryngoscopes ; Laryngoscopy*

BACKGROUND: During laryngoscopy, force applied to the soft tissue are assumed to cause circulatory response. The aim of the study was to evaluate this circulatory response and to analyze the relationship between the intensity of the force and the magnitude of the associated circulatory responses. METHODS: Sixty-three healthy patients, aged 17 to 29 years, were randomly allocated to one of three groups according to the three different subjective forces applied intentionally. Subjects in group 1 received minimal force enough to stimulate circulatory response, but not enough to expose the glottis. Group 2 received the optimal force necessary to expose the glottic opening. Group 3 received excessive force to expose the glottic opening. The axial forces of the laryngoscope handle with a Macintosh blade were measured during a ten-second laryngoscopy, and peak force, mean force, and area under the curve were calculated. Then, arterial pressure and heart rate were recorded after the laryngoscopy at 30 seconds intervals for 3 minutes. The data was compared among groups and with the baseline post-induction values. RESULTS: No significant difference was found in heart rate and blood pressure at each interval among the three groups, with increasing arterial pressure and heart rate after the laryngoscopy. Blood pressure and heart rate were maintained high, being progressively higher in the groups receiving a higher force. CONCLUSIONS: We conclude that little association was found between the force and the magnitude of circulatory response although higher forces cause longer circulatory responses.
Arterial Pressure ; Blood Pressure ; Glottis ; Heart Rate ; Humans ; Intention ; Laryngoscopes ; Laryngoscopy*

From March 1985 to Sep.1985, Transcatheter hepatic arterial embolization was perfromed in 17 primary heptomaand 8 metstasis of liver in Department of Radiology, Yonsei University College of Medicine. Metastatic cancers ofliver were one nasopharyngeal cancer, one small bowel leiomyosarcoma, one gall bladder cancer and 5 colon cancers.The used embolization materials were the followings: Gelfoam particles for one primary hepatoma, 95% absoluteethanol for 4 patients, Ivalon(250-590micro m) for 19 patients and autologous blood clots for one metastasis, Theresults were summarized as the follows: 1. The devascularization of tumor vessels in post-emblization hepaticangiogram was complete in 6 primary hepatom and one metastasis and partial in 11 primary hepatoma and 7metastasis. 2. In the follow-up CT evaluation 3 to 4 weeks after embolization, well necrotic density was revealedin 8 primary hepatoma and one metastasis. 3. The complications were fever with higher than 38 degrees C(92%),abdominal pain (72%) and nausia or vomiting(40%). They were subsided wtihin one to 7 days after embolization. 4.In liver function study, sGOT and sGPT were elevated in 80% of total cases and returned to normal within 15 to 30days. LDH was variable. In 4 cases of absolute ethanol infusion, above liver enzymes were markedly elvated as 10times or more as normal range.
Alanine Transaminase ; Aspartate Aminotransferases ; Carcinoma, Hepatocellular ; Colon ; Ethanol ; Fever ; Follow-Up Studies ; Gallbladder Neoplasms ; Gelatin Sponge, Absorbable ; Hepatic Artery ; Humans ; Leiomyosarcoma ; Liver Neoplasms ; Liver ; Nasopharyngeal Neoplasms ; Neoplasm Metastasis ; Reference Values

No abstract available.
Gram-Positive Bacterial Infections* ; Teicoplanin*

Ultrasonograms of proven liver abscesses in 44 patients were analysed. In ulltrasonography prior to otherdiagnostic approach, 38 patients(86.4%) were accurately diagnosed as liver abscess with correlation of clinicalsymptoms. The outline of abscess is smoothly defined. oval and round in 19 patients, irregularly and ill-definedin 25 patients. Only in 5 patients echogenic capsules are demonstrated. The internal echogenecity is variable;they are predominantly echo-free in 14, predominantly low-echo in 25 and predominantly echogenic, similar to solidtumor in 2 patients . 36 patients who were treated by medication only and combined needle aspiration had follow-up ultrasonography within 3 weeks since initial treatment. 33 patients were ultrasonically and clinically improved.Only one patients died of sepsis after needle aspiration and 2 patients were discharged without any sign ofimprovement.
Abscess ; Capsules ; Follow-Up Studies ; Humans ; Liver Abscess ; Liver ; Needles ; Sepsis ; Ultrasonography

No abstract available.
Allografts* ; Humans ; Living Donors* ; Risk Factors*

No abstract available.
Allografts* ; Humans ; Living Donors* ; Risk Factors*

No abstract available.
Ureter*